Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Annovis Bio, Inc.

Ticker
ANVS
Sector
Industry
Report date
November 14, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments for Annovis Bio include capital raises through public offerings, regulatory compliance progress with the NYSE, clinical trial enrollment milestones, and collaborations to support NDA submission using AI.

Recent developments:
  • Annovis Bio reported preliminary cash and cash equivalents of approximately $2.8 million as of November 2026 [N1].
  • The company received a NYSE listing notice and plans to regain compliance [N2].
  • Annovis Bio is collaborating with Weave Bio on AI use in the NDA submission process for buntanetap [N3].
  • The pivotal Phase 3 Alzheimer's trial of buntanetap achieved full enrollment [N4].
  • Annovis Bio regained NYSE compliance ahead of an 18-month cure period [N5].
  • The company announced pricing of a $15 million public offering in May 2026 [N6].
  • Annovis launched a $10 million underwritten offering in April 2026 [N7].
  • Canaccord Genuity maintained a buy recommendation on Annovis Bio as of September 2025 [N8].
Overview

Annovis Bio, Inc. is focused on developing therapeutics for neurodegenerative diseases, primarily Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead candidate, buntanetap, is an orally administered small molecule designed to inhibit the overproduction of multiple neurotoxic proteins (APP, tau, alpha-synuclein, TDP43) that contribute to neurodegeneration. The company is conducting a pivotal Phase 3 trial in early AD patients and an open-label extension study in PD patients, with plans for a Parkinson's disease dementia study contingent on funding. Clinical data from earlier Phase 1/2 and Phase 2/3 trials have shown statistically significant improvements in cognition and motor function. Annovis aims to develop a disease-modifying drug that addresses multiple neurotoxic proteins simultaneously, a novel approach in the neurodegeneration field. The company has a leadership team with extensive industry experience and has raised capital through multiple public offerings to fund ongoing clinical development and regulatory activities.

Executive summary

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company developing buntanetap, an oral drug candidate targeting multiple neurotoxic proteins implicated in Alzheimer's and Parkinson's diseases. The company is conducting pivotal Phase 3 trials in early AD and ongoing extension studies in PD, with prior clinical data showing improvements in cognition and motor function. Financially, as of September 30, 2026, Annovis reported cash and equivalents of approximately $2.8 million, current assets of $7.8 million, current liabilities of $6.3 million, and a net loss of $9.5 million for the quarter. Recent developments include successful capital raises, regulatory compliance progress with the NYSE, and collaborations to support NDA submission. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for ANVS

Bull case model:

Annovis Bio's lead candidate buntanetap has shown statistically significant improvements in cognition and motor function in clinical trials for Alzheimer's and Parkinson's diseases, addressing multiple neurotoxic proteins implicated in disease pathology. The ongoing pivotal Phase 3 trial in early AD and extension studies in PD represent critical steps toward potential regulatory submissions. The company's ability to raise capital through public offerings and maintain NYSE compliance supports continued development. Collaborations incorporating AI in NDA submission processes may enhance regulatory efficiency. If clinical and regulatory milestones are met, buntanetap could represent a novel therapeutic option with a unique mechanism of action in neurodegenerative diseases.

Bear case model:

The development of disease-modifying therapies for neurodegenerative diseases is highly challenging, with significant scientific and regulatory hurdles. Despite promising early clinical data, the pivotal Phase 3 trial outcomes remain uncertain, and failure to demonstrate efficacy or safety could impede approval. Financial constraints are notable given the net losses and limited cash reserves reported, necessitating further capital raises which may dilute shareholders. Regulatory compliance risks exist, as indicated by recent NYSE listing notices requiring corrective actions. The competitive landscape includes other companies pursuing neurodegeneration therapies, and the complexity of targeting multiple neurotoxic proteins may present unforeseen challenges in clinical development and commercialization.

Moat:

Annovis Bio's potential competitive advantage lies in its unique mechanism of action targeting multiple neurotoxic proteins simultaneously, rather than a single protein, which may address the complex pathology of neurodegenerative diseases more effectively. The company has conducted extensive clinical studies with over 1,200 patients treated, demonstrating tolerability and preliminary efficacy signals. Its lead candidate buntanetap is orally administered and brain-penetrant, which may offer patient convenience and compliance benefits. The company's focused pipeline on neurodegeneration, regulatory progress with the FDA, and collaborations leveraging AI for NDA submission further support its differentiated position. However, the biotech sector's inherent risks and the challenges of demonstrating disease modification in neurodegeneration remain significant.

Risks overview
Risks summary
The most significant risks for Annovis Bio include the uncertainty of clinical trial outcomes for its lead candidate buntanetap, financial sustainability given current cash levels and ongoing losses, and regulatory compliance challenges with the NYSE.
Risks details:

• Clinical Trial Risk: The pivotal Phase 3 trial in early Alzheimer's disease and ongoing studies in Parkinson's disease may not demonstrate sufficient efficacy or safety to support regulatory approval.
• Financial Risk: The company reported a net loss of approximately $9.46 million for the quarter ending September 30, 2026, with cash and equivalents of about $2.8 million, indicating a need for additional financing to sustain operations.
• Regulatory Risk: Annovis received NYSE listing notices and is undertaking measures to regain compliance, which poses risks related to continued listing and regulatory scrutiny.
• Development and Commercialization Risk: The novel mechanism targeting multiple neurotoxic proteins may face unforeseen challenges in clinical development, manufacturing, and market acceptance.

FINAL FORECAST FOR ANVS

Final take one line
Annovis Bio has detailed clinical and regulatory disclosures with active development of buntanetap targeting neurodegenerative diseases, supported by recent financing and compliance progress.
Final take 12 to 24 month view

Business trends: Continued clinical development of buntanetap in pivotal Phase 3 trials for Alzheimer's and extension studies in Parkinson's disease, with a focus on multi-target neurotoxic protein inhibition.
Execution milestones: Completion of Phase 3 trial enrollment, ongoing regulatory interactions including NDA submission preparations, and capital raises to fund operations.
Key risks: Clinical trial outcome uncertainty, financial sustainability given current cash and losses, and regulatory compliance challenges with NYSE listing.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Annovis Bio, Inc. is a late-stage clinical drug platform company focused on neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD).
  • The lead product candidate is buntanetap, an orally administered small molecule designed to inhibit synthesis of multiple neurotoxic proteins (APP, tau, alpha-synuclein, TDP43) implicated in neurodegeneration.
  • Buntanetap's mechanism involves increasing affinity between a special mRNA region (5'UTR iron responsive element) and Iron Regulatory Protein-1 to reduce translation of neurotoxic proteins, aiming to restore nerve cell function and reduce inflammation.
  • The company is conducting a pivotal Phase 3 study in early AD patients (NCT06709014) with a 6-month symptomatic efficacy period followed by 12 months for disease-modifying efficacy.
  • An open-label extension (OLE) study in PD patients is ongoing, enrolling 500 patients treated for up to 36 months or until market approval.
  • A planned study in Parkinson's disease dementia (PDD) is under refinement and contingent on funding.
  • Completed clinical studies include Phase 1/2 trials in early AD and PD patients showing statistical improvements in cognition and function, and a Phase 3 PD trial completed in December 2023 with topline data showing improvements in cognition and motor function in subgroups.
  • The Phase 2/3 AD trial completed in February 2024 showed statistically significant dose-dependent improvement in ADAS-Cog11 scores in early AD patients.
  • The FDA has provided guidance supporting a regulatory path with potential NDA filings for short-term and long-term efficacy based on the Phase 3 AD trial design.
  • The company has a pipeline including buntanetap for chronic neurodegeneration, ANVS405 for acute neurodegeneration (e.g., traumatic brain injury), and ANVS301 for advanced AD.
  • Leadership includes founder and CEO Maria L. Maccecchini, CFO Mark Guerin, SVP R&D Cheng Fang, SVP Regulatory Eve Damiano, and others with extensive industry experience.
  • Financial snapshot as of 2026-09-30 shows cash and cash equivalents of approximately $2.82 million, current assets of about $7.81 million (from 2024-03-31), current liabilities of about $6.26 million, a current ratio of 1.25, and a cash ratio of 0.45.
  • Net income for the quarter ending 2026-09-30 was a loss of approximately $9.46 million, with basic and diluted EPS of -$0.22 per share.
  • Recent news includes closing a $21 million offering to fund operations through the Phase 3 Alzheimer's readout, NYSE listing notice with plans to regain compliance, collaboration with Weave Bio on AI use in NDA submission for buntanetap, and full enrollment in the pivotal Phase 3 Alzheimer's trial.
  • The company regained NYSE compliance ahead of an 18-month cure period and announced multiple public offerings in 2026 to support development.
  • Annovis has reported preliminary cash and cash equivalents of approximately $2.8 million as of November 2026.
  • Canaccord Genuity maintained a buy recommendation on Annovis Bio as of September 2025.
  • The company has conducted over 1,200 human patient treatments with buntanetap, showing consistent tolerability and minimal side effects.
  • The company emphasizes its unique approach targeting multiple neurotoxic proteins simultaneously, aiming to develop a disease-modifying drug for neurodegeneration.
  • The toxic cascade targeted by buntanetap involves high neurotoxic protein levels leading to impaired axonal transport, inflammation, nerve cell death, and loss of cognition and motor function.
  • The company has ongoing clinical and regulatory activities including FDA meetings and protocol approvals for extension studies.
  • Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-13 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-05 | www.nasdaq.com | Annovis Bio, Inc. Reports Preliminary Cash and Cash Equivalents of approximately $2.8 million | https://www.nasdaq.com/articles/annovis-bio-inc-reports-preliminary-cash-and-cash-equivalents-approximately-28-million
  • N2 | 2026-11-02 | www.nasdaq.com | Annovis Gets NYSE Listing Notice; Plans To Regain Compliance | https://www.nasdaq.com/articles/annovis-gets-nyse-listing-notice-plans-regain-compliance
  • N3 | 2026-09-23 | www.nasdaq.com | Annovis Collaborates With Weave Bio On AI Use In NDA Submission For Butanetap | https://www.nasdaq.com/articles/annovis-collaborates-weave-bio-ai-use-nda-submission-butanetap
  • N4 | 2026-07-08 | www.nasdaq.com | Annovis Bio Jumps On Full Enrollment In Pivotal Phase 3 Alzheimer's Trial Of Buntanetap | https://www.nasdaq.com/articles/annovis-bio-jumps-full-enrollment-pivotal-phase-3-alzheimers-trial-buntanetap
  • N5 | 2026-05-27 | www.nasdaq.com | Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period | https://www.nasdaq.com/articles/annovis-bio-regains-nyse-compliance-ahead-18-month-cure-period
  • N6 | 2026-05-21 | www.nasdaq.com | Annovis Announces Pricing Of $15 Mln Public Offering | https://www.nasdaq.com/articles/annovis-announces-pricing-15-mln-public-offering
  • N7 | 2026-04-09 | www.nasdaq.com | Annoivs Bio Launches $10M Underwritten Offering | https://www.nasdaq.com/articles/annoivs-bio-launches-10m-underwritten-offering
  • N8 | 2025-09-30 | www.nasdaq.com | Canaccord Genuity Maintains Annovis Bio (ANVS) Buy Recommendation | https://www.nasdaq.com/articles/canaccord-genuity-maintains-annovis-bio-anvs-buy-recommendation
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine